Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

Recruiting

Phase 2

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBCNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

Sponsor:

University of Kansas Medical Center

Code:

NCT05645380

Conditions

Triple Negative Breast Cancer

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Docetaxel

Doxorubicin

Cyclophosphamide

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by University of Kansas Medical Center on 2024-08-26.